Boston Scientific (NYSE:BSX) Updates FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.870-2.940 for the period, compared to the consensus estimate of 2.880. The company issued revenue guidance of $19.3 billion-$19.6 billion, compared to the consensus revenue estimate of $19.5 billion. Boston Scientific also updated its Q2 2025 guidance to 0.710-0.730 EPS.

Boston Scientific Trading Up 1.2%

BSX stock traded up $1.19 on Friday, reaching $99.75. The company's stock had a trading volume of 6,325,460 shares, compared to its average volume of 6,537,560. The firm has a market cap of $147.58 billion, a PE ratio of 79.78, a PEG ratio of 2.79 and a beta of 0.68. The business has a fifty day simple moving average of $100.84 and a two-hundred day simple moving average of $98.62. Boston Scientific has a 12-month low of $71.88 and a 12-month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same period in the prior year, the business earned $0.56 EPS. The company's revenue for the quarter was up 20.9% on a year-over-year basis. As a group, research analysts forecast that Boston Scientific will post 2.85 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on BSX. Wall Street Zen raised Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Argus set a $130.00 price target on Boston Scientific in a research report on Tuesday, February 18th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Robert W. Baird increased their price objective on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Finally, Barclays boosted their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Twenty-one research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $116.00.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer now directly owns 1,476,882 shares of the company's stock, valued at $153,137,894.58. This represents a 10.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total value of $5,799,551.36. Following the completion of the sale, the executive vice president now directly owns 178,342 shares of the company's stock, valued at $18,347,824.96. The trade was a 24.02% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 411,970 shares of company stock valued at $42,406,693. Corporate insiders own 0.50% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC raised its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,376 shares of the medical equipment provider's stock after buying an additional 226 shares during the period. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.